» Articles » PMID: 32388224

Development of a Robust Functional Cell-based Assay for Replacing the Rabbit Blood Sugar Bioidentity Test of Insulin Glargine Drug Substance

Overview
Specialty Chemistry
Date 2020 May 11
PMID 32388224
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

A rabbit blood sugar bioidentity assay is required by the FDA to evaluate biological activity for all insulin and its analogs per USP<121> guideline. Not only are a large number of live animals used, but the rabbit blood sugar method is also highly variable and expensive. Our goal is to develop a functional cell-based assay to replace rabbit blood sugar method. An H4IIE G6P-Luc reporter assay was developed by utilizing insulin's role in regulating hepatic gluconeogenesis pathway. It is known that Glucose 6-phosphatase is a rate-limiting enzyme in the gluconeogenesis pathway, and the mRNA expression of its catalytic subunit, G6PC, is highly regulated by insulin. A G6P-Luc stable cell line in H4IIE hepatocytes was first generated by stably expressing luciferase reporter gene driven by human G6PC promoter via lentivirus technology. The cell-based assay was developed and optimized to demonstrate good dose-dependent responsiveness to insulin. We further qualified the assay with two analysts through multiple runs, and demonstrated excellent performance characteristics of linearity, accuracy, and precision. A robustness study was then conducted to define critical factors for assay performance. We compared this newly developed assay with a previously established cell-based pIR MSD assay, which measures insulin receptor phosphorylation (pIR) in HepG2 cell line using Meso-Scale Discovery (MSD) technology. The comparability study was conducted to compare the two assays using samples generated from forced degradation. This study showed high correlation between assays, and both are stability indicating. Compared with the pIR MSD assay, the G6P-Luc assay not only has a significantly lower variability in qualification studies, but also offers many other advantages, including ease of use in a quality control laboratory with fewer steps, lower cost, and does not depend on a single vendor. In conclusion, we have developed a physiologically relevant and robust functional cell-based assay that is suitable to replace rabbit blood sugar method.

Citing Articles

Development of a Cell-Based Reporter Potency Assay for Live Virus Vaccines.

Sun D, Meyer B, Deevi D, Mirza A, He L, Gruber A Vaccines (Basel). 2024; 12(7).

PMID: 39066407 PMC: 11281433. DOI: 10.3390/vaccines12070769.


The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of Biosimilars.

Niazi S Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004383 PMC: 10674418. DOI: 10.3390/ph16111517.


Progress towards the Replacement of the Rabbit Blood Sugar Test for the Quantitative Determination of the Biological Activity of Insulins (USP <121>) with an In Vitro Assay.

Ruggeberg S, Wanglin A, Demirel O, Hack R, Niederhaus B, Bidlingmaier B Animals (Basel). 2023; 13(18).

PMID: 37760353 PMC: 10525547. DOI: 10.3390/ani13182953.


In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart.

Mishra A, Deshmane R, Thappa D, Lona J, Ghade N, Sonar S BioDrugs. 2023; 37(5):709-719.

PMID: 37285012 DOI: 10.1007/s40259-023-00607-4.


Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro.

Garige M, Ghosh S, Roelofs B, Rao V, Sourbier C Methods Protoc. 2023; 6(2).

PMID: 37104015 PMC: 10144404. DOI: 10.3390/mps6020033.